VEREGEN (sinecatechins) by ANI Pharmaceuticals is unknown. First approved in 2006.
Drug data last refreshed Yesterday
Veregen is a topical ointment containing sinecatechins approved for basal cell carcinoma (BCC). Its mechanism of action is not fully characterized, though in vitro studies suggest anti-oxidative activity. The clinical significance of this mechanism remains unknown.
With only ~6 months until patent expiration and minimal Medicare utilization ($235K annual spending), the brand team faces imminent loss of exclusivity and will likely be restructured.
unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
Worked on VEREGEN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Zero linked job postings indicate minimal ongoing recruitment for Veregen-focused roles. Career visibility is extremely low, reflecting the product's marginal commercial status and imminent LOE.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo